India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
Gas-based power plants in India are currently operating at a low Plant Load Factor (PLF),…
The Central Industrial Security Force (CISF) Raising Day is observed annually on March 10 to…
In Indian history, some rulers became famous not only for their power but also for…
The Dead Sea is a special saltwater lake located between Jordan and Israel in the…
On March 7, 2025, Bank of Baroda (BoB) introduced the ‘bob Global Women NRE &…
The SBI Clerk Mains Exam 2025 is expected to be conducted in April 2025, and…